Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$8.55 - $111.89 $11.8 Million - $155 Million
-1,385,465 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$76.53 - $110.43 $50.5 Million - $72.9 Million
-660,188 Reduced 32.27%
1,385,465 $147 Million
Q2 2021

Aug 16, 2021

SELL
$85.37 - $114.1 $19.8 Million - $26.4 Million
-231,373 Reduced 10.16%
2,045,653 $175 Million
Q1 2021

May 14, 2021

SELL
$109.73 - $153.66 $68.6 Million - $96 Million
-624,802 Reduced 21.53%
2,277,026 $261 Million
Q4 2020

Feb 12, 2021

SELL
$79.58 - $152.45 $54.4 Million - $104 Million
-683,672 Reduced 19.07%
2,901,828 $406 Million
Q3 2020

Nov 13, 2020

BUY
$66.43 - $90.99 $9.47 Million - $13 Million
142,490 Added 4.14%
3,585,500 $292 Million
Q2 2020

Aug 14, 2020

SELL
$44.04 - $80.69 $5.5 Million - $10.1 Million
-124,901 Reduced 3.5%
3,443,010 $247 Million
Q1 2020

May 15, 2020

SELL
$44.49 - $93.39 $19.3 Million - $40.5 Million
-433,399 Reduced 10.83%
3,567,911 $159 Million
Q4 2019

Feb 18, 2020

BUY
$66.49 - $137.73 $39.4 Million - $81.6 Million
592,503 Added 17.38%
4,001,310 $382 Million
Q3 2019

Nov 14, 2019

BUY
$31.0 - $89.73 $56 Million - $162 Million
1,805,751 Added 112.64%
3,408,807 $268 Million
Q2 2019

Aug 14, 2019

BUY
$36.0 - $44.73 $8.11 Million - $10.1 Million
225,275 Added 16.35%
1,603,056 $69.5 Million
Q1 2019

May 15, 2019

BUY
$33.79 - $51.99 $14 Million - $21.5 Million
414,434 Added 43.02%
1,377,781 $55.8 Million
Q4 2018

Feb 14, 2019

BUY
$31.59 - $62.65 $4.14 Million - $8.21 Million
131,012 Added 15.74%
963,347 $50.4 Million
Q3 2018

Nov 14, 2018

BUY
$31.25 - $47.64 $26 Million - $39.7 Million
832,335 New
832,335 $37.4 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $74.6M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Capital International Investors Portfolio

Follow Capital International Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.